Optimizing Timing of Valve Intervention in Patients With Asymptomatic Severe Valvular Heart Disease
| Autor: | Jean-François Dorval, Laurent Jamart, Arsène Basmadjian, Patrick Garceau, Denis Bouchard, Michel Pellerin, Anique Ducharme, Anita W. Asgar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Psychological intervention Heart Valve Diseases Disease 030204 cardiovascular system & hematology Asymptomatic Severity of Illness Index Time Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Mitral valve Intervention (counseling) medicine Humans 030212 general & internal medicine Intensive care medicine Heart Valve Prosthesis Implantation Mitral regurgitation business.industry valvular heart disease medicine.disease medicine.anatomical_structure Cohort Asymptomatic Diseases Risk Adjustment medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Canadian journal of cardiology. 37(7) |
| ISSN: | 1916-7075 |
| Popis: | The management of valvular heart disease has changed dramatically over the past decade with advances in cardiac imaging, the use of novel biomarkers, and the development of transcatheter valve repair and replacement technology. International society guidelines have kept pace to provide recommendations for diagnosis, follow-up, and timing of intervention. The most challenging patient cohort for clinicians are patients with asymptomatic severe disease in whom the optimal timing of intervention can be ill-defined. It is a fine balance between the risks of early intervention on asymptomatic patients and improving patient outcomes by preventing long-term cardiac complications. The key in optimal patient management is gathering the necessary information on patient risk and combining that with the risk, efficacy, and durability of valve interventions to arrive at the appropriate timing for intervention. This group of patients will be the focus of this review as we delve into the natural history, recommended follow-up, and indications for intervention in patients with degenerative aortic and mitral valve disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect